EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform

Hernan H M da Costa iD, Monica Bielavsky, Diego J B Orts iD, Sergio Araujo, Patrícia P Adriani, Juliana S Nogueira, Renato M Astray iD, Ramendra P Pandey iD, Marcelo Lancellotti, Jair P Cunha-Junior, Carlos R Prudencio iD

International Journal of Molecular Sciences · 11.09.2023 · 24 (18) · 13955

DOI: 10.3390/ijms241813955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.09.2023. Verfasst von Hernan H M da Costa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Center, Adolfo Lutz Institute, São Paulo 01246-902, Brazil. Hauptthemen laut MEDLINE: Zika Virus, Zika Virus Infection, Viral Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Council for Scientific and Technological Development, Coordination for the Improvement of Higher Education Personnel, São Paulo Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Zika Virus (ZIKV) is an emerging arbovirus of great public health concern, particularly in the Americas after its last outbreak in 2015. There are still major challenges regarding disease control, and there is no ZIKV vaccine currently approved for human use. Among many different vaccine platforms currently under study, the recombinant envelope protein from Zika Virus (rEZIKV) constitutes an alternative option for vaccine development and has great potential for monitoring ZIKV infection and antibody response. This study describes a method to obtain a bioactive and functional rEZIKV using an E. coli expression system, with the aid of a 5-L airlift bioreactor and following an automated fast protein liquid chromatography (FPLC) protocol, capable of obtaining high yields of approximately 20 mg of recombinant protein per liter of bacterium cultures. The purified rEZIKV presented preserved antigenicity and immunogenicity. Our results show that the use of an airlift bioreactor for the production of rEZIKV is ideal for establishing protocols and further research on ZIKV vaccines bioprocess, representing a promising system for the production of a ZIKV envelope recombinant protein-based vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zika VirusZika Virus InfectionViral VaccinesHumansViral Envelope ProteinsAntibodies, NeutralizingEscherichia coliAntibodies, ViralVaccines, SubunitRecombinant ProteinsBioreactors

Stichwörter der Autor:innen

FPLCZika Virusairlift bioreactorenvelope proteinrEZIKVrecombinant protein

Substanzen

Viral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralViral VaccinesVaccines, SubunitRecombinant Proteins

Autor:innen und Institutionen

  • Immunology Center, Adolfo Lutz Institute, São Paulo 01246-902, Brazil.
  • Interunits Graduate Program in Biotechnology, University of São Paulo, São Paulo 05508-000, Brazil.
  • Laboratory of Cardiobiology, Department of Biophysics, Paulista School of Medicine, Federal University of Sao Paulo, São Paulo 04023-062, Brazil.
  • Skinzymes Biotechnology Ltd., São Paulo 05441-040, Brazil.
  • Laboratory of Nanopharmaceuticals and Delivery Systems, Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
  • Virology Center, Adolfo Lutz Institute, São Paulo 01246-902, Brazil.

ORCID-Profile: Hernan H M da Costa, Diego J B Orts, Renato M Astray, Ramendra P Pandey, Carlos R Prudencio

Förderung

  • National Council for Scientific and Technological Development
  • Coordination for the Improvement of Higher Education Personnel
  • São Paulo Research Foundation
  • Special Health Fund for Mass Immunization and Disease Control of the State Department of Health of the State of São Paulo
  • Ministry of Health, Special Health Fund for Mass Immunization and Disease Control of the State Department of Health of the State of São Paulo (FESIMA)

Zitieren

APA

da Costa, H. H. M., Bielavsky, M., Orts, D. J. B., Araujo, S., Adriani, P. P., Nogueira, J. S., Astray, R. M., Pandey, R. P., Lancellotti, M., Cunha-Junior, J. P., & Prudencio, C. R. (2023). Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform. International Journal of Molecular Sciences, 24(18), 13955. https://doi.org/10.3390/ijms241813955

Vancouver

da Costa HHM, Bielavsky M, Orts DJB, Araujo S, Adriani PP, Nogueira JS, et al. Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform. International Journal of Molecular Sciences. 2023;24(18):13955. doi:10.3390/ijms241813955

BibTeX
@article{daCosta2023,
  author = {da Costa, Hernan H M and Bielavsky, Monica and Orts, Diego J B and Araujo, Sergio and Adriani, Patrícia P and Nogueira, Juliana S and Astray, Renato M and Pandey, Ramendra P and Lancellotti, Marcelo and Cunha-Junior, Jair P and Prudencio, Carlos R},
  title = {Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {18},
  pages = {13955},
  doi = {10.3390/ijms241813955}
}
Kostenlos starten →